Recombinant pegRNA for improving gene editing efficiency and application thereof

By introducing lock-like sequences and quadruple helical structures into pegRNA, the problem of low editing efficiency caused by secondary structure errors and terminal degradation of pegRNA was solved, and gene editing efficiency was significantly improved, especially for efficient editing at specific sites and disease-related sites.

CN118995709AActive Publication Date: 2024-11-22NORTHEAST AGRICULTURAL UNIVERSITY

Patent Information

Application Number
CN202411165770.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-23
Publication Date
2024-11-22
Estimated Expiration
2044-08-23

AI Technical Summary

Technical Problem

pegRNAs are prone to low editing efficiency during gene editing due to secondary structure errors or terminal degradation, especially at certain specific sites and disease-related sites.

Method used

Introducing locking sequences and quadruple helical structures into pegRNAs stabilizes the secondary structure, increases GC content, protects the ends, prevents enzymatic degradation, and improves the stability and editing efficiency of pegRNAs.

Benefits of technology

It significantly improved gene editing efficiency, especially at specific and disease-related sites, and enhanced the functional stability and editing accuracy of pegRNA.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118995709A_ABST
    Figure CN118995709A_ABST
Patent Text Reader

Abstract

The invention discloses recombinant pegRNA capable of improving gene editing efficiency and application of the recombinant pegRNA, and belongs to the technical field of biology. The invention aims to provide a gene editing tool in order to improve the gene editing efficiency. According to the recombinant pegRNA capable of improving the gene editing efficiency, a pegRNA sequence is taken as a starting sequence, and 53rd-56th basic groups are replaced into a lock-shaped sequence. And a more effective tool is provided for gene editing.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biotechnology, and specifically relates to a recombinant pegRNA for improving gene editing efficiency and an application thereof. Background Art

[0002] Prime editor is a highly accurate and versatile editor derived from the CRISPR / Cas9 system. pegRNA contains a spacer sequence for guiding the PE protein to the genomic target site, and an extension sequence at the 3' end. The extension sequence from 5' to 3' is RTT containing the expected editing sequence and a PBS sequence that is complementary to the target site. In the cell, the PE protein-pegRNA complex binds to a specific site on the DNA site through the spacer sequence of the pegRNA, and the double-stranded DNA is pulled to form an R loop, in which the non-targeted strand is cut by PE to form an incision. The incision releases a 3' end and pairs with PBS and RTT, and then uses RTT as a template to produce a 3'flap containing the expected editing sequence under the action of reverse transcriptase. 3'flap invades a single strand through a sequence homologous to the downstream genomic sequence. During this period, the 5'flap generated by the incision will compete with the 3'flap. Although the 5'flap with more homologous sequences is more likely to hybridize with the non-edited strand, the 5'flap is more likely to be removed by the endonuclease FEN1 and the exonuclease EXO1. The successfully invaded 3'flap generates heteroduplex DNA containing the expected edit under the action of the ligase. Finally, during DNA replication or repair, the heteroduplex will be eliminated, producing double-stranded DNA containing the expected edit or restoring to the wild-type DNA sequence. Primeeditor can perform all types of DNA changes such as base conversion, transversion, insertion, and deletion in the mammalian cell genome without the need to generate double-strand breaks in the DNA.

[0003] In PE, pegRNA is responsible for binding to the PE complex and targeting it to the target site. In addition, the RTT sequence of pegRNA also carries the expected editing information. Whether pegRNA is expressed normally, how much it is expressed, and whether it can be stably present in the correct form will affect the efficiency of PE. Due to its special sequence composition, pegRNA will form an incorrect secondary structure and the exposed terminal sequence is easily degraded, resulting in reduced activity of pegRNA and thus affecting the editing efficiency.

[0004] When editing certain special sites, pegRNA will form an incorrect secondary structure due to the particularity of the spacer sequence, resulting in low editing efficiency. In addition, the 3'extension part of pegRNA plays an important role in the PE system as a template required for PE editing and has the function of initiating reverse transcription. However, pegRNA may be exposed to an environment containing ribonucleases in the complex formed with the RT protein, which will lead to the degradation of the 3'extension of pegRNA. The degraded pegRNA cannot produce the correct reverse transcription results. The RNP complex formed by the degraded pegRNA containing 3'extension and RT will compete with the normal RNP complex for binding to the target DNA, resulting in a decrease in PE efficiency. Summary of the invention

[0005] The purpose of the present invention is to improve the efficiency of gene editing and provide a gene editing tool.

[0006] The present invention provides a recombinant pegRNA for improving gene editing efficiency, wherein the pegRNA sequence is used as a starting sequence, and the bases at positions 53 to 56 are replaced with a lock sequence.

[0007] It is further defined that the recombinant pegRNA also includes a quadruplex sequence inserted at the 3' end.

[0008] It is further defined that the quadruple helix sequence is shown as SEQ ID NO.2.

[0009] It is further defined that the structure of the pegRNA also includes, from 5' to 3' direction, a spacer sequence, a scaffold sequence, a transcription template containing the expected editing sequence, and a PBS sequence that complementarily binds to the target site; the sequence of the lock structure is shown in SEQ ID NO.1.

[0010] It is further defined that the scaffold sequence is shown as SEQ ID NO.7.

[0011] The present invention provides an application of the above-mentioned recombinant pegRNA in improving gene editing efficiency.

[0012] The present invention provides an application of the above-mentioned recombinant pegRNA vector or recombinant microbial cell in improving gene editing efficiency.

[0013] It is further defined that the gene is HEK3, DNMT1, FANCF, Alzheimer's disease-related gene APP or diabetes-related gene SLC30A8; and the gene editing refers to base substitution, base deletion or base insertion.

[0014] The present invention provides a kit for improving gene editing efficiency, wherein the kit comprises the above-mentioned histotype pegRNA.

[0015] It is further defined that the kit also includes nCas9-RT protein and ngRNA.

[0016] To further define, the method for constructing nCas9-RT protein is as follows: using pCMV-PE2 plasmid as the basic vector, it is digested with EcoRⅠ, and then the sequence P2A-EGFP-P2A-PURO with restriction sites at both ends is connected to the vector to obtain an intermediate vector, and then the intermediate vector is digested with PciⅠ, and the left and right homologous arms containing the restriction sites in the middle are constructed into the vector to obtain the final AAVS1-KI vector.

[0017] Beneficial effects: Adding a lock sequence (GGACTTCGGTCC, SEQ ID NO.1) to pegRNA provides a nucleation site for the secondary structure of pegRNA, which helps the correct formation of the secondary structure of pegRNA. Adding a quadruplex (TTCCTCTGCATCTCGTGCTCAGTCTGGGGGTGGCCTGGGAGGG, SEQ ID NO.2) sequence to the 3' end of pegRNA protects the end of pegRNA from being degraded by enzymes in the cell.

[0018] When pegRNA is functioning, its efficiency will be reduced due to two reasons. First, when it is functioning in the cell, the terminal of pegRNA will be degraded, resulting in a decrease in the number of pegRNAs that can function, which will lead to a decrease in efficiency. Secondly, when editing certain special sites, pegRNA is prone to form an incorrect secondary structure. The incorrect secondary structure will cause pegRNA to be unable to form a complex with nCas9, resulting in a lower efficiency at these special sites. In view of the defects of these two pegRNAs, two modifications have been made to pegRNA: (1) adding GC base pairs to the second stem-loop structure of pegRNA to increase the GC content in the stem-loop structure. There are three hydrogen bonds between GC and two hydrogen bonds between AT. Increasing the GC content provides a stable site for the correct folding of pegRNA and the formation of a stable secondary structure, reducing the formation of an incorrect secondary structure. (2) Adding a four-stranded helix sequence of RNA to the end can reduce the degradation of the terminal of pegRNA by RNA enzymes in the body, prolong the survival time of pegRNA in the body, and improve the efficiency of gene editing.

[0019] In order to verify the gene editing ability of the optimized pegRNA in the PE system, three types of gene sites were selected for testing. Five sites are often used for gene editing efficiency testing: (1) HEK3, DNMT1, and FANCF. Three types of editing were designed at these three sites: single base substitution, 24bp insertion, and 15bp deletion; (2) GPSM2. The pegRNA targeting this site will form different degrees of mismatch due to the particularity of the spacer sequence, thereby forming an incorrect secondary structure; (3) APP and SLC30A8, two disease treatment-related sites. The editing results show that the improved pegRNA can improve the PE editing efficiency. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 Schematic diagram of pegRNA; A: Schematic diagram of optimized pegRNA sequence; B: Schematic diagram of 4 pegRNA structures NC-pegRNA: unchanged pegRNA; L-pegRNA: a structure with high GC content is added to the first stem-loop structure of the pegRNA backbone; G-pegRNA: a four-stranded helix body sequence is added to the end of the pegRNA; LG-pegRNA: a structure with high GC content is added to the first stem-loop structure of the backbone and a four-stranded helix body sequence is added to the end;

[0021] Figure 2 Comparison of free energy of pegRNA with different secondary structures;

[0022] Figure 3 Schematic diagram of the stability test process of optimized pegRNA in nuclear lysate;

[0023] Figure 4 Results of stability test of optimized pegRNA in nuclear lysate; A: Electrophoresis of stability test of optimized pegRNA and unoptimized pegRNA; B: Corresponding to A Figure 4 Grayscale analysis of pegRNA electrophoresis bands;

[0024] Figure 5 Schematic diagram of gene knock-in targeting AAVS1 locus;

[0025] Figure 6 The structure and identification results of AAVS1-KI vector; A: AAVS1-KI vector map; B: AAVS1-KI vector and vector enzyme digestion product electrophoresis, M is Marker; lane 1 is the electrophoresis of AAVS1-KI vector alone, with a length of 12832bp; lane 2 is the product of HindⅢ and MluⅠ digestion of AAVS1-KI vector, with lengths of 2866bp and 9966bp respectively; C: AAVS1-KI vector sequencing results;

[0026] Figure 7 Flowchart for constructing a HEK293T cell line that stably expresses Prime editor proteins;

[0027] Figure 8 Results of constructing cell lines; A: electrophoresis after AAVS1-KI vector digestion and purification; B: HEK293T cells expressing Prime editor protein under a fluorescent microscope;

[0028] Fig. 9 It is the result of DNA level identification; M is Marker; lane 1 is the result of 5' end identification, with a length of 1110 bp; lane 2 is the result of middle identification, with a length of 999 bp;

[0029] Fig.10 The results of protein level identification are shown in Figure 1. A: Western blot was used to detect the expression of nCas9-RT protein, with β-ACTIN as the internal reference protein. B: Grayscale analysis of protein bands, with the ordinate being the ratio of nCas9-RT protein to β-ACTIN protein, and 11 and 14 being compared with WT, respectively.

[0030] Fig.11 Schematic diagram of three types of editing at the HEK3 site; Note: The yellow line indicates the pegRNA targeting position, red indicates single base substitution, green indicates 24bp insertion, and magenta indicates 15bp deletion; the nCas9 incision is recorded as the +1 position, and the downstream direction is recorded as +2, etc.;

[0031] Fig.12 Schematic diagram of optimized pegRNA-driven PE3;

[0032] Fig.13 The results of ngRNA expression plasmid construction and sequencing identification; A: ngRNA plasmid construction process; B: electrophoresis detection of the constructed ngRNA expression plasmid; M is a marker, lanes 1 to 6 are the electrophoresis diagrams of ngRNA expression plasmids corresponding to APP, SLC30A8, HEK3, DNMT1, FANCF, and GPSM2, with a length of 2279 bp; C: ngRNA expression plasmid sequencing verification results;

[0033] Fig.14 Flowchart for editing using optimized pegRNA;

[0034] Fig.15 This is the electrophoresis diagram of deep sequencing sample bands;

[0035] Fig.16The effect of optimized pegRNA on single-base editing efficiency; AC: NC, L, G, LG refer to NC-pegRNA, L-pegRNA, G-pegRNA, LG-pegRNA, respectively. In each bar graph, the L, G, and LG groups are compared with the NC group. Only the groups with significant differences are marked in the figure, and those without marking have no significant differences;

[0036] Fig.17 The effect of optimized pegRNA on insertion editing efficiency; AC: NC, L, G, LG refer to NC-pegRNA, L-pegRNA, G-pegRNA, LG-pegRNA, respectively. In each bar graph, the L, G, and LG groups are compared with the NC group. Only the groups with significant differences are marked in the figure, and those without marking have no significant differences;

[0037] Fig.18 The effect of optimized pegRNA on deletion editing efficiency; AC: NC, L, G, LG refer to NC-pegRNA, L-pegRNA, G-pegRNA, LG-pegRNA, respectively. In each bar graph, the L, G, and LG groups are compared with the NC group. Only the groups with significant differences are marked in the figure, and those without marking have no significant differences.

[0038] Fig.19 Prediction of secondary structure of pegRNA targeting GPSM2 site; A: Schematic diagram of mismatched structure of pegRNA at GPSM2 site; B: Prediction of secondary structure of four pegRNAs at GPSM2 site;

[0039] Fig. 20 is the editing efficiency of GPSM2 locus; Note: NC, L, G, and LG refer to NC-pegRNA, L-pegRNA, G-pegRNA, and LG-pegRNA, respectively. In each bar graph, the L, G, and LG groups are compared with the NC group. Only the groups with significant differences are indicated in the figure, and those without indication are without significant differences;

[0040] Fig.21 This is a schematic diagram of base modification at the APP and SLC30A8 sites;

[0041] Fig. 22 Editing efficiency of optimized pegRNA at APP and SLC30A8 sites for deep sequencing detection; Note: The part marked by the red box is the expected editing;

[0042] Fig.23To optimize the editing efficiency of pegRNA at APP and SLC30A8 sites; AB: NC, L, G, and LG refer to NC-pegRNA, L-pegRNA, G-pegRNA, and LG-pegRNA, respectively. In each bar graph, the L, G, and LG groups were compared with the NC group. Only the groups with significant differences are indicated in the figure, and those not indicated have no significant differences. DETAILED DESCRIPTION

[0043] The pCMV-PE2 plasmid was provided by Fenghui Biological Company, ZT281.

[0044] BPK1520 plasmid was purchased from Addgene: BPK1520.

[0045] 5'modifications to CRISPR-Cas9 gRNA can change the dynamics and size of R-loops and inhibit DNA cleavage. Literature records stem-loop structures, kink structures, and hairpin structures.

[0046] Example 1. Method for constructing pegRNA

[0047] Structure Figure 1 As shown, Figure 1 A in it is LG-pegRNA;

[0048] NC-pegRNA without any changes, SEQ ID NO.3: NNNNNNNNNNNNNNNNNNNGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGTTATC AACTTGAAAAAGTGGCACCGAGTCGGTGCNNNNNNNNNNNNNNNNNNNNNNNNN;

[0049] L-pegRNA containing only a structure with high GC content, SEQ ID NO.4: NNNNNNNNNNNNNNNNNNNNNGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGTTATC AACTTGGACTTCGGTCCAAGTGGCACCGAGTCGGTGCNNNNNNNNNNNNNNNNNNNNNNNNNNNN; the GC content after the change is 66.6%.

[0050] G-pegRNA containing only four-stranded spirochetal structure, SEQ ID NO.5: NNNNNNNNNNNNNNNNNGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGT TATCAACTTGAAAAAGTGGCACCGAGTCGGTGCNNNNNNNNNNNNNNNNNNNNNTTCCT CTGCCATCTCGTGCTCAGTCTGGGGGTGGGCCTGGGAGGG;

[0051] LG-pegRNA containing a structure with high GC content and a quadruple helix structureSEQ ID NO.6:NNNNNNNNNNNNNNNNNNNGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGT TATCAACTTGGACTTCGGTCCAAGTGGCACCGAGTCGGTGCNNNNNNNNNNNNNNNNNNNNNNNNNN NNNTTCCTCTGCCATCTCGTGCTCAGTCTGGGGGTGGGCCTGGGAGGG.

[0052] Scaffold sequence, SEQ ID NO. 7: GTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTGC.

[0053] Example 2. Optimized pegRNA secondary structure prediction

[0054] The free energies of different pegRNAs at all sites in Example 1 were statistically analyzed, and the free energies of the four pegRNAs were listed and displayed in violin plots. The results showed that compared with the unmodified NC-pegRNA, the free energy of the L-pegRNA with a high GC content structure was significantly reduced, and the free energy of the G-pegRNA with a four-stranded helix sequence was also reduced, but not as significantly as that of the L-pegRNA. The free energy of the LG-pegRNA with both sequences added was the most significantly reduced ( Figure 2 ). This suggests that these two modifications will make the structure of pegRNA more stable, thereby affecting the efficiency of gene editing.

[0055] Example 3. Study on the stability of optimized pegRNA in nuclear lysate

[0056] 1. Stability test

[0057] 1. Extraction of Nuclear Protein

[0058] (1) Transfer the cultured HEK293T cells to a centrifuge tube, centrifuge at 4°C, 3000 rpm for 10 min, discard the culture medium, add 10 mL of pre-cooled 1× PBS, centrifuge at 4°C, 3000 rpm for 5 min, and repeat the washing twice.

[0059] (2) Add 5 μL of phosphatase inhibitor, 10 μL of PMSF and 1 μL of DTT to each 1 mL of pre-cooled Hypotonic Buffer, mix well and keep on ice until use. Add 5 μL of phosphatase inhibitor, 10 μL of PMSF and 1 μL of DTT to each 1 mL of pre-cooled Lysis Buffer and keep on ice until use.

[0060] (3) According to the calculation of every 1×10 7 Add 0.6mL to 0.9mL Hypotonic Buffer per cell to the above centrifuge tube.

[0061] (4) Tap the tube wall with your finger to suspend the precipitate. Place the tube in an ice bath for 10 min and oscillate for 10 s to mix.

[0062] (5) Centrifuge the suspension at 4°C, 3000 rpm for 5 min, discard the supernatant immediately, add 0.4 mL of pre-cooled Hypotonic Buffer and wash the precipitate by shaking for 30 s. Centrifuge again at 4°C, 5000 rpm for 5 min, discard the supernatant, and retain the precipitate.

[0063] (6) Add 0.2 mL of prepared Lysis Buffer to the precipitate and oscillate to suspend the precipitate. Place the precipitate on ice for 20 min, centrifuge at 15,000 rpm for 10 min at 4°C, discard the precipitate, aliquot the supernatant and store at -80°C.

[0064] 2. Prepare the system according to the components and concentrations in Table 1 below, and add 0.5 μg of pegRNA to the system.

[0065] Table 1 PCR reaction system

[0066]

[0067] (2) After incubating the above system at 37°C for 20 min, an equal volume of RNA Buffer was added and electrophoresed in a 2% agarose gel. Grayscale analysis was performed using ImageJ.

[0068] Results: In order to better simulate the function of pegRNA in cells, this study used the method of incubating pegRNA with nuclear lysate in vitro to verify the stability of pegRNA ( Figure 3 ). Nuclear lysate (nuclear extract) was obtained, and then a mixture containing 3 μL nuclear extract, 1 μL Tris-HCL, 1 μL MgCl 2 , 1μL NaCl, 1μL DTT, 1μL NTP, 1μL RNase inhibitor. Add 0.5μg of NC-pegRNA, L-pegRNA, G-pegRNA, and LG-pegRNA to the mixed solution (for example, HEK3 site), incubate at 37°C for 20 minutes, add RNA Buffer to terminate the reaction, and perform electrophoresis in 2% agarose gel. Place the agarose gel in an imager for imaging, and use ImageJ to perform grayscale analysis on the brightness of the bands.

[0069] Taking the pegRNA of HEK3 locus as an example, the incubation experiment was carried out. The sequence is shown in Table 10. The results show that the modified L-pegRNA, G-pegRNA, and LG-pegRNA have stronger stability in nuclear lysate ( Figure 4 ).

[0070] Example 3. Optimized pegRNA-driven gene editing

[0071] The construction of HEK293T cell lines that stably express PE protein, when using conventional Prime editors for gene editing, usually the PE protein expression plasmid and the pegRNA expression plasmid are simultaneously transferred into the cells, and expressed in the cells to form an RNP complex. This study intends to insert a gene expressing PE protein into the AAVS1 safe site of HEK293T cells, so that PE protein can be stably expressed in the cells.

[0072] 1. Site knock-in vector construction strategy

[0073] 1. Construction of AAVS1 knock-in plasmid

[0074] Design the homology arm sequence and sgRNA sequence required for knock-in. The AAVS1 site has been proven to be a "safe site" in the genome, which can accept the insertion and expression of exogenous fragments without adverse effects. According to the design principles of sgRNA, the spacer sequence of the sgRNA targeting the AAVS1 site is: AGAGCUAGCACAGACUAGAG. Select fragments of 800 bp on both sides of the cleavage site as the sequence of the homology arm ( Figure 5 ).

[0075] This study used pCMV-PE2 plasmid (Addgene: pCMV-PE2) as the basic vector. The main functional elements of pCMV-PE2 plasmid include CMV promoter, CMV enhancer, Cas9 (H840A) protein and reverse transcriptase fused with it. First, EcoRⅠ was used for digestion, and then the sequence P2A-EGFP-P2A-PURO with restriction sites at both ends was connected to the vector to obtain an intermediate vector. Then, PciⅠ was used for digestion of the intermediate vector, and the left and right homologous arms containing restriction sites in the middle were constructed into the vector to obtain the final AAVS1-KI vector.

[0076] P2A is a self-cleaving peptide and does not play a major role in the experimental purpose; EGFP is used for cell screening; PURO is used for drug screening after cell electroporation:

[0077] P2A-EGFP-P2A-PURO,SEQ ID NO.8:

[0078]

[0079] The left and right homology arms containing restriction sites in the middle are used for vector insertion through homologous recombination; the restriction sites are used to linearize the plasmid vector:

[0080] The left and right homology arms containing the restriction site in the middle are SEQ ID NO.9:

[0081]

[0082] 2. Verification of AAVS1 site knock-in vector

[0083] The constructed AAVS1-KI plasmid ( Figure 6 A) in the figure was subjected to agarose gel electrophoresis, and it can be seen that the vector size is correct. The AAVS1-KI plasmid was double-digested with HindⅢ and MluⅠ restriction enzymes, and fragments of 2866bp and 9966bp were generated after enzyme digestion. Agarose gel electrophoresis showed that the bands were correct ( Figure 6 B). Sanger sequencing of the inserted homology arms and the added restriction sites showed that the constructed partial sequence was correct and no mutations were generated ( Figure 6 C).

[0084] 3. Gene knock-in targeting AAVS1 locus in HEK293T cells

[0085] 1. Recovery of HEK293T cells

[0086] Take out the frozen cells from the -80℃ refrigerator or liquid nitrogen tank, immediately put them into liquid nitrogen and take them to the experimental site, then quickly shake the cell cryopreservation tube in a 37℃ water bath to quickly thaw the frozen cells, transfer the cells from the cryopreservation tube to a centrifuge tube containing culture medium, centrifuge at 1200rpm for 3min, remove the supernatant and add culture medium to resuspend the cell pellet, and inoculate the resuspended cell suspension into an appropriate culture dish for culture.

[0087] HEK293T cells were cultured in 15% FBS medium at 37°C and 5% CO 2 , the culture medium needs to be replaced every day.

[0088] Transfection of HEK293T cells

[0089] (1) Electroporation of HEK293T cells

[0090] 1) First, discard the old culture medium in HEK293T cells and add DPBS for washing.

[0091] 2) Add warm 0.25% trypsin and digest at 37°C for 1 min, then add twice the volume of culture medium of trypsin to terminate digestion.

[0092] 3) Use a pipette to gently blow up the cells to resuspend them, then add the cell suspension to a 15 mL centrifuge tube, centrifuge at 1200 rpm for 3 min, carefully discard the supernatant, and then resuspend the cell pellet in fresh culture medium.

[0093] 4) Count the cells.

[0094] 5) Calculate the volume of cell suspension to be added based on the cell concentration. The required volume is about 1×10 6 cells.

[0095] 6) Prepare a plasmid mixture by adding Opti-MEM to 5 μg of DNA (AAVS1-KI vector) to make up to 20 μL.

[0096] 7) Use the plasmid mixture to 1×10 6 The pellet of each cell was resuspended and the suspension was transferred to a new electroporation cup, which was placed in an electroporator and electroporated according to the preset HEK293T cell program, 150V, 10ms, 10 times.

[0097] 8) Add 150 μL of Opti-MEM to the electroporated cells and balance for 5 min. Inoculate into a cell culture plate for culture.

[0098] Identification of positive clones of HEK293T cells

[0099] (1) PCR identification

[0100] The collected monoclonal cell samples were identified according to the following system and procedures.

[0101] Table 2 PCR reaction system

[0102]

[0103] Table 3 PCR reaction program

[0104]

[0105] In order to obtain HEK293T cells that stably express the Prime editor protein, the verified AAVS1-KI plasmid was transferred into wild-type HEK293T cells using electroporation according to the following process ( Figure 7 ).

[0106] The AAVS1-KI plasmid was digested with HindⅢ restriction endonuclease to linearize the vector. After linearization, phenol chloroform was used for extraction to remove impurities such as restriction endonucleases and small DNA fragments. The extracted linear DNA was subjected to agarose electrophoresis to check whether the bands were correct. The results showed that the size of the bands after enzyme digestion and extraction was correct and the single cut was clear ( Figure 8 A in the figure). Two groups of cells were set up, one for the experimental group into which the AAVS1-KI linearized vector was transferred, and the other for the wild-type control group. The vector was transferred into the cells according to the electroporation method, and the electroporation program was 150V, 10ms, 10 times. The cell status and fluorescence were observed every day during the cell culture period ( Figure 8B), 1 mg / mL Puro was added 72 h after electroporation for drug screening. During drug screening, the number of cells in the experimental group and the wild-type control group was observed every day. After all cells in the wild-type control group died, the experimental group stopped adding drugs and returned to normal culture medium. The cells that completed drug screening were then diluted and identified.

[0107] Verification of the results of gene knock-in targeting the AAVS1 site in HEK293T cells (verification of the monoclonal cell suspension obtained by transferring the AAVS1-KI plasmid into HEK293T cells):

[0108] 10 μL of cell suspension containing monoclonal cells was added to 50 μL of cell lysis buffer and lysed according to the program of 55°C, 1h, 99°C, 30min. Using the lysate as a template, using primers 5'-F, 5'-R; 3'-F, 3'-R; middle-F, middle-R, (p1, 2, 5, 6, 3, 4), as shown in Table 4, DNA level knock-in identification was performed to ensure that the vector was inserted into the correct site in the correct way. As shown in the results, bands of 1110bp and 999bp were detected at the 5' end and the middle part, respectively ( Fig. 9 ).

[0109] Table 4

[0110]

[0111]

[0112] In order to further verify whether the correctly inserted vector can produce functional proteins (the test object is the monoclonal cells obtained by transferring the AAVS1-KI plasmid into HEK293T cells). Western blot experiments were performed using antibodies against Cas9. In order to make the results more credible, this study conducted experiments on monoclonal #11, which was correctly identified at the DNA level, monoclonal #14, which was incorrectly identified at the DNA level, and wild-type HEK293T cells. The results showed that Cas9 expression was detected only in cells #11 ( Fig.10 ), which indicated that the obtained #11 cells were correctly inserted with the AAVS1-KI vector and could be used for subsequent experiments.

[0113] Example 4. Editing of Optimized pegRNA at Selected Sites

[0114] Optimized pegRNA editing at different gene loci

[0115] In order to better verify the gene editing ability of the optimized pegRNA in the PE system, this study selected three types of gene loci for testing. First, in order to explore the role of the optimized pegRNA in different types of editing, this study selected three loci that are often used for gene editing efficiency testing: HEK3, DNMT1, and FANCF, and designed three types of editing at these three loci: single base substitution, 24bp insertion, and 15bp deletion ( Fig.11 ). Using the primers in Table 9, slow annealing was used to obtain ngRNA of HEK3, DNMT1, and FANCF genes. The collected samples were amplified and sent to the company for deep sequencing. The efficiency was directly obtained by sequencing data analysis. Table 5 shows four pegRNAs of HEK3, DNMT1, and FANCF genes.

[0116] Table 5 DNA sequences of pegRNA used in this article

[0117]

[0118]

[0119]

[0120]

[0121] 1. Construction of ngRNA expression plasmid

[0122] (1) Slow annealing of spacer (taking HEK3 as an example), add the following system:

[0123] Table 6 Slow annealing reaction system

[0124]

[0125] After mixing, bring it to a boil and cool it to room temperature before use

[0126] (2) Enzyme digestion of BPK1520 plasmid, the system is as follows:

[0127] Table 7 DNA restriction endonuclease digestion reaction system

[0128]

[0129] The digestion reaction conditions are selected according to the restriction endonuclease requirements. The digestion products are purified and set aside for later use.

[0130] (3) The annealed spacer is connected to the BPK1520 vector after restriction digestion. The system is as follows:

[0131] Table 8T4 ligation reaction system

[0132]

[0133] Table 9

[0134]

[0135] Using the PE3 system (ngRNA, a pegRNA, nCas9-RT protein), HEK293T cells transfected (AAVS1-KI vector) contain nCas9-RT protein to edit different sites ( Fig.12 ), the PE3 system requires an additional sgRNA to cut the non-targeting chain, so the ngRNA expression plasmid is first constructed ( Fig.13 A in the figure). Two single-stranded DNA oligonucleotides corresponding to the sgRNA spacer part were synthesized, and each component was added according to the slow annealing system. The PCR instrument was used for programmed slow annealing. The BPK1520 plasmid containing the sgRNA backbone sequence was digested with the restriction enzyme BbsI to generate a vector with sticky ends. Then, the fragment obtained by slow annealing was connected to the vector after digestion using T4 DNA ligase. After transformation, bacterial culture, sequencing, plasmid extraction, etc., the plasmid expressing ngRNA was obtained. The electrophoresis and sequencing results showed that the vector was correct ( Fig.13 B and C in ).

[0136] Using the synthesized DNA sequence containing T7 promoter as a template, pegRNA (DNA sequence of pegRNA in Table 9) was transcribed in vitro; using the obtained ngRNA expression plasmid as a template, PCR amplification was performed using primers containing T7 promoter sequence to obtain a linear DNA fragment containing T7 promoter sequence (the downstream primer is T7-R, and then the upstream primers of different genes are the primers in Table 10, and the obtained linear DNA fragment containing T7 promoter sequence and sgRNA sequence is sequence 1), and the linear DNA fragment of sgRNA sequence is sequence 1. Using sequence 1 as a template, in vitro transcription was performed to obtain ngRNA. Then, the constructed HEK293T (HEK293T transfected with AAVS1-KI vector) that can stably express PE protein was used as the experimental object, and pegRNA and ngRNA targeting different genes and performing different types of gene editing were transferred into cells by liposome transfection (simultaneous transfection, peg is 20ng, ng is 10ng). Since liposomes are toxic to cells, the medium was changed within 24 hours of transfection, and the cells were cultured for 72 hours. The cells transfected with pegRNA were sampled and the gene editing efficiency was detected by deep sequencing and analyzed using CRISPResso2 software ( Fig.14 ).

[0137] The T7 promoter sequence is TAATACGACTCACTATAGGG.

[0138] Table 10

[0139] HEK3-ngRNA-F TAATACGACTCACTATAGGGTCAACCAGTATCCCGGTGC, SEQ ID NO.75 DNMT1-ngRNA-F TAATACGACTCACTATAGGGCCCTTCAGCTAAAATAAAGG, SEQ ID NO.76 FANCF-ngRNA-F TAATACGACTCACTATAGGGGGGTCCCAGGTGCTGACGT, SEQ ID NO.77 SLC30A8-ngRNA-F TAATACGACTCACTATAGGGACATTTGGATGGCACTGAGC, SEQ ID NO.78 APP-ngRNA-F TAATACGACTCACTATAGGCTTCATATCCTGAGTCATGT, SEQ ID NO.79 GPSM2-ngRNA-F TAATACGACTCACTATAGGAACATAAGGTTTCTCAAAGA, SEQ ID NO.80 T7-R GCACCGACTCGGTGCCACTT, SEQ ID NO.81

[0140] Transfection of HEK293T cells

[0141] 1) Seed the cells into 48-well plates one day in advance and prepare for transfection when the cells grow to about 60% confluence.

[0142] 2) Use Opti-MEM medium to dilute Lipofectamine3000 reagent and pegRNA.

[0143] 3) Add Opti-MEM to the diluted pegRNA and ngRNA to make up to 50 μL.

[0144] 4) Mix the diluted Lipofectamine 3000 reagent and the diluted pegRNA and ngRNA, and incubate at room temperature for 15 minutes. Pay attention to the operation time and do not let the incubation time exceed.

[0145] 5) Add the liposome and RNA complex dropwise to the cells that have been replaced with fresh culture medium. Note that the addition should be done in a clockwise direction.

[0146] 6) Place in a 37°C incubator for culture.

[0147] Isolation of positive clones of HEK293T cells

[0148] Use the limiting dilution method to pick a single clone. The specific steps are as follows:

[0149] (1) Digest the cells after drug screening, add the cell suspension to a 15 mL EP tube, centrifuge at 800 rpm for 2 min, and then resuspend the cells in 1 mL of DMEM medium.

[0150] (2) Take 20 μL of cell suspension for counting.

[0151] (3) Based on the measured cell number, dilute the cell suspension to contain 200 cells per ml.

[0152] (4) Pipette 1 mL of the diluted cell suspension and add 19 mL of DMEM medium.

[0153] (5) Add 20 mL of the prepared culture medium suspension to each well of a 96-well plate at a rate of 200 μL and place in an incubator for incubation.

[0154] (6) When the cells are cultured for 4 days, observe the cell growth under a microscope and replace the medium in the wells containing cells. When the cells are cultured for 7 days, observe under a microscope to see if they are monoclonal cells. If they are monoclonal cells, mark them and continue to culture them, and discard the medium in the remaining wells.

[0155] (7) Continue to culture the cells until they form clusters, digest the cells in the wells and inoculate them into a 24-well plate, and continue to culture until samples can be harvested.

[0156] 2. Preparation of deep sequencing samples

[0157] Amplification of DNA fragments at editing sites using gene site selection strategies

[0158] (1) PCR amplification of the editing site DNA fragment

[0159] The PCR reaction system is as follows

[0160] Table 11 PCR reaction system

[0161]

[0162] The PCR reaction procedure is as follows

[0163] Table 12 PCR reaction program

[0164]

[0165] The collected cells were lysed using a lysis buffer according to the program at 55°C for 1 h and 99°C for 30 min to obtain cell genomic DNA, and the genomic DNA was used as a template to amplify the target site using site-specific primers (primer sequences in Table 13) to obtain a single target band ( Fig.15 ), and send the target product to the company to detect the gene editing status of the target site through deep sequencing.

[0166] Table 13

[0167]

[0168] Secondly, in order to explore the function of optimized pegRNA in resisting misfolding, this study selected a "bad" site: GPSM2. The pegRNA targeting this site will form different degrees of mismatch due to the particularity of the spacer sequence, thereby forming an incorrect secondary structure.

[0169] Finally, in order to detect the actual application effect of the optimized pegRNA, this study selected two disease treatment-related sites: APP and SLC30A8, and detected the resulting editing efficiency.

[0170] 3. Detection and analysis of editing results

[0171] Next-generation sequencing analysis editing efficiency: The prepared short-fragment DNA (150-300 bp) was sent to Hangzhou Kaitai Biotechnology Co., Ltd. for library construction and sequencing. The raw data obtained by sequencing was screened for quality control using fastp (0.23.4) software, and the data was processed using preset parameters without additional parameter restrictions.

[0172] The analysis of sequencing data was completed using CRISPResso2 (version 2.1.3). CRISPResso2 was run in the Linux system and analyzed using PE mode and HDR mode respectively. The following basic commands were entered in PE mode: -r1, -r2, --prime_editing_pegRNA_spacer_seq, --prime_editing_pegRNA_extension_seq, --prime_editing_nicking_guide_seq, --amplicon_seq, --prime_editing_pegRNA_scaffold_seq. The following basic commands were entered in HDR mode: -r1, -r2, -a, -g, -e. In addition, the following commands were entered to limit other parameters: -w, --min_frequency_alleles_around_cut_to_plot, --write_cleaned_report, --place_report_in_output_folder, -n.

[0173] (1) Optimized pegRNA-driven single-base editing

[0174] In the single-base substitution editing of HEK3, DNMT1, and FANCF, L-pegRNA improved the efficiency of single-base editing at HEK3, DNMT1, and FANCF sites; G-pegRNA improved the efficiency of egg base editing at HEK3, DNMT1, and FANCF sites; LG-pegRNA improved the efficiency of single-base editing at HEK3, DNMT1, and FANCF sites. ( Fig.16 ).

[0175] (2) Optimized pegRNA-driven insertional editing

[0176] In the insertion editing of the three sites of HEK3, DNMT1, and FANCF, compared with the control group, L-pegRNA improved the editing efficiency of gene insertion at the HEK3, DNMT1, and FANCF sites; G-pegRNA improved the efficiency of gene insertion editing at the HEK3, DNMT1, and FANCF sites; LG-pegRNA improved the editing efficiency of gene insertion at the HEK3, DNMT1, and FANCF sites. ( Fig.17 ).

[0177] (3) Optimized pegRNA-driven deletion editing

[0178] In the deletion editing of the three sites of HEK3, DNMT1, and FANCF, L-pegRNA improved the efficiency of gene editing at the HEK3 and DNMT1 sites; G-pegRNA improved the efficiency of gene editing at the HEK3 and DNMT1 sites; LG-pegRNA significantly improved the efficiency of gene editing at the HEK3 site ( Fig.18 ).

[0179] (4) Optimized pegRNA editing at bad sites

[0180] In this study, the GPSM2 site was selected to investigate the editing efficiency of optimized pegRNA at specific sites.

[0181] Since pegRNA contains a PBS sequence complementary to the non-targeting strand, pegRNA will generally form an incorrect structure of spacer and 3'extension. Based on this, we designed the insertion of three bases of GAA at the +2 position of the GPSM2 site. This change will make the pegRNA form perfect complementarity. As shown in the pegRNA secondary structure prediction results, the red box is the part of the mismatched complement ( Fig.19 ).

[0182] The results showed that in the GPSM2 locus, L-pegRNA, G-pegRNA, and LG-pegRNA all increased the efficiency of gene editing compared with the control group ( Fig. 20 ).

[0183] (5) Optimized pegRNA editing at disease-related sites

[0184] In the Alzheimer's disease-related gene APP and the diabetes-related gene SLC30A8, point mutations that have been reported to be related to disease treatment were designed. The specific base changes are shown in the figure below ( Fig.21 ). Four pegRNAs were used for transfection at each gene locus and the editing efficiency was tested.

[0185] The results showed that the expected editing occurred at both sites ( Fig. 22 Compared with the control group, L-pegRNA improved the gene editing efficiency at two sites; G-pegRNA significantly improved the gene editing efficiency at both sites; LG-pegRNA significantly improved the gene editing efficiency at APP and SLC30A8 sites ( Fig.23 ).

Claims

1. A recombinant pegRNA that improves gene editing efficiency, It is characterized in that Using the pegRNA sequence as the starting sequence, bases 53 to 56 were replaced with a padlock sequence.

2. The recombinant pegRNA according to claim 1, It is characterized in that The recombinant pegRNA also includes a quadruplex sequence inserted at the 3' end.

3. The recombinant pegRNA according to claim 2, It is characterized in that The sequence of the quadruplex is shown in SEQ ID NO.

2.

4. The recombinant pegRNA according to claim 1, It is characterized in that The structure of the pegRNA also includes, from 5' to 3', a spacer sequence, a scaffold sequence, a transcription template containing an expected editing sequence, and a PBS sequence complementary to the target site; the sequence of the lock structure is shown in SEQ ID NO.

1.

5. The recombinant pegRNA according to claim 4, It is characterized in that The scaffold sequence is shown as SEQ ID NO.

7.

6. Use of the recombinant pegRNA according to any one of claims 1 to 5 in improving gene editing efficiency.

7. Use of a vector or recombinant microbial cell containing the recombinant pegRNA according to any one of claims 1 to 5 in improving gene editing efficiency.

8. The use according to claim 6 or 7, It is characterized in that The genes are HEK3, DNMT1, FANCF, Alzheimer's disease-related gene APP or diabetes-related gene SLC30A8; the gene editing refers to base substitution, base deletion or base insertion.

9. A kit for improving gene editing efficiency, It is characterized in that The kit comprises the histotype pegRNA according to any one of claims 1-4.

10. The kit according to claim 9, It is characterized in that The kit also includes nCas9-RT protein and ngRNA.

Citation Information

Patent Citations

  • Novel gene editing system and related vector and method

    CN113549648A

  • Base editing tool and construction method thereof

    CN113637672A

  • Compositions and methods for immunotherapy

    CN114729368A

  • Pair of auxiliary guide RNA / guide RNA for editing human PCSK9 nucleic acid sequence

    CN116656676A

  • RNAmotif sequence and application thereof in improving pilot editing efficiency

    CN118497203A

Cited By

  • Construction method of Alzheimer's disease model pig based on endogenous multi-gene editing

    CN120536504A